title: Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons.
abstract: Both HIV infection and methamphetamine dependence can be associated with brain dysfunction. Little is known, however, about the cognitive effects of concurrent HIV infection and methamphetamine dependence. The present study included 200 participants in 4 groups: HIV infected/methamphetamine dependent (HIV+/METH+), HIV negative/methamphetamine dependent (HIV-/METH+), HIV infected/methamphetamine nondependent (HIV+/METH-), and HIV negative/methamphetamine nondependent (HIV-/METH-). Study groups were comparable for age, education, and ethnicity, although the HIV-/METH- group had significantly more females. A comprehensive, demographically corrected neuropsychological battery was administered yielding a global performance score and scores for seven neurobehavioral domains. Rates of neuropsychological impairment were determined by cutoff scores derived from performances of a separate control group and validated with larger samples of HIV+ and HIV- participants from an independent cohort. Rates of global neuropsychological impairment were higher in the HIV+/METH+ (58%), HIV-/METH+ (40%) and HIV+/METH- (38%) groups compared to the HIV-/METH- (18%) group. Nonparametric analyses revealed a significant monotonic trend for global cognitive status across groups, with least impairment in the control group and highest prevalence of impairment in the group with concurrent HIV infection and methamphetamine dependence. The results indicate that HIV infection and methamphetamine dependence are each associated with neuropsychological deficits, and suggest that these factors in combination are associated with additive deleterious cognitive effects. This additivity may reflect common pathways to neural injury involving both cytotoxic and apoptotic mechanisms.
authors.affiliation: Department of Psychiatry, University of California, San Diego School of Medicine, San Diego, California, USA.
authors.forename: Julie D
authors.initials: JD
authors.lastname: Rippeth
authors.forename: Robert K
authors.initials: RK
authors.lastname: Heaton
authors.forename: Catherine L
authors.initials: CL
authors.lastname: Carey
authors.forename: Thomas D
authors.initials: TD
authors.lastname: Marcotte
authors.forename: David J
authors.initials: DJ
authors.lastname: Moore
authors.forename: Raul
authors.initials: R
authors.lastname: Gonzalez
authors.forename: Tanya
authors.initials: T
authors.lastname: Wolfson
authors.forename: Igor
authors.initials: I
authors.lastname: Grant
mesh_terms: D000328:Adult; D001921:Brain / Q000187:drug effects / Q000503:physiopathology; D003072:Cognition Disorders / Q000175:diagnosis / Q000209:etiology*; D005260:Female; D006679:HIV Seropositivity / Q000150:complications* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008694:Methamphetamine / Q000009:adverse effects; D009483:Neuropsychological Tests; D012720:Severity of Illness Index; D019966:Substance-Related Disorders / Q000150:complications* / Q000503:physiopathology
chemical_list: D008694:Methamphetamine